Chemical Compound Review:
Droloxifene 3-[(E)-1-[4-(2- dimethylaminoethoxy)phenyl]...
Synonyms:
Droloxifeno, Droloxifenum, E-Droloxifene, CHEMBL487, SureCN4842, ...
- Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7. Roos, W., Oeze, L., Löser, R., Eppenberger, U. J. Natl. Cancer Inst. (1983)
- Induction of CYP2B1 and 3A1, and associated monoxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. White, I.N., Davies, A., Smith, L.L., Dawson, S., De Matteis, F. Biochem. Pharmacol. (1993)
- Oestrogenic activity of tamoxifen and its metabolites on gene regulation and cell proliferation in MCF-7 breast cancer cells. Johnson, M.D., Westley, B.R., May, F.E. Br. J. Cancer (1989)
- Cytochrome P-450 3A and 2D6 catalyze ortho hydroxylation of 4-hydroxytamoxifen and 3-hydroxytamoxifen (droloxifene) yielding tamoxifen catechol: involvement of catechols in covalent binding to hepatic proteins. Dehal, S.S., Kupfer, D. Drug Metab. Dispos. (1999)
- Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. Geisler, J., Ekse, D., Hösch, S., Lønning, P.E. J. Steroid Biochem. Mol. Biol. (1995)
- Droloxifene (3-hydroxytamoxifen) has membrane antioxidant ability: potential relevance to its mechanism of therapeutic action in breast cancer. Wiseman, H., Smith, C., Halliwell, B., Cannon, M., Arnstein, H.R., Lennard, M.S. Cancer Lett. (1992)
- Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Zhao, X.J., Jones, D.R., Wang, Y.H., Grimm, S.W., Hall, S.D. Xenobiotica (2002)